76
Antihyperlipide mic Agents

Antihyperlipidemic Agents

Embed Size (px)

Citation preview

Page 1: Antihyperlipidemic Agents

Antihyperlipidemic Agents

Page 2: Antihyperlipidemic Agents

Antihyperlipidemic agents are a diverse group of pharmaceuticals that are used in the treatment of hyperlipidemias.

Page 3: Antihyperlipidemic Agents

What’s Hyperlipidemia?

Page 4: Antihyperlipidemic Agents

Hyperlipidemia is the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood (serum)

Page 5: Antihyperlipidemic Agents

Normal Lipid profile(in mg/dl):

Cholesterol < 200

Triglycerides < 150

HDL (High-Density Lipoprotein) > 60 LDL (Low-Density Lipoprotein) < 130

Cholesterol to HDL Ratio < 3.4 (no unit)

Page 6: Antihyperlipidemic Agents

There are five types of Hyperlipidemia(hyperlipoproteinemia), each with a different profile of blood fat and a different set of associated risks of heart disease.

Page 7: Antihyperlipidemic Agents

V IV III IIb IIa I TypeFamilial mixed hypertriglyceridemia

Familial hypertriglyceridemia

Familial dysbetalipoproteinemia

Familial mixed hyperlipidemia

Familial hypercholesterolemia

Familial Hyperchylomicronemia

Scientific Name

VLDL,Chylomiron

VLDL IDL VLDL,LDL LDL Chylomicron Increased Lipoprotein Class

Increased production of decreased clearance of VLDL and Chylomicrons

Overproduction or decreased removal of VLDL TG in serum

Overproduction or underutilization of IDL

Overproduction of VLDL by liver

Defect in synthesis or processing of LDL receptors

Deficiency of lipoprotein lipase or apolipoprotein CII

Cause

Nacin, fibrate,statin

Niacin,fibrate

Nacin, fibrate,statin

Bile acid-sequestrantand niacin or statin

Bile acid-sequestrantand niacin or statin

Low fat diet intake

Treatment

Page 8: Antihyperlipidemic Agents

V IV III IIb IIa I TypeFamilial mixed hypertriglyceridemia

Familial hypertriglyceridemia

Familial dysbetalipoproteinemia

Familial mixed hyperlipidemia

Familial hypercholesterolemia

Familial Hyperchylomicronemia

Scientific Name

VLDL,Chylomiron

VLDL IDL VLDL,LDL LDL Chylomicron Increased Lipoprotein Class

Increased production of decreased clearance of VLDL and Chylomicrons

Overproduction or decreased removal of VLDL TG in serum

Overproduction or underutilization of IDL

Overproduction of VLDL by liver

Defect in synthesis or processing of LDL receptors

Deficiency of lipoprotein lipase or apolipoprotein CII

Cause

Nacin, fibrate,statin

Niacin,fibrate

Nacin, fibrate,statin

Bile acid-sequestrantand niacin or statin

Bile acid-sequestrantand niacin or statin

Low fat diet intake

Treatment

All types require low fat diet intake

Page 9: Antihyperlipidemic Agents

Antihyperlipidemic drugs include:

• Statins• Fibrates• Bile Acid Sequestrants• Nicotinic Acid• Ezetimibe

Page 10: Antihyperlipidemic Agents

Serum Cholesterol Cellular Cholesterol

Diet Biosynthesis

Bile Acids

Intestine

Feces

Re-absorption

Lipoproteincatabolism

Page 11: Antihyperlipidemic Agents

Serum Cholesterol Cellular Cholesterol

Diet Biosynthesis

Bile Acids

Intestine

Feces

Re-absorption

Lipoproteincatabolism

STATINS

Page 12: Antihyperlipidemic Agents

Serum Cholesterol Cellular Cholesterol

Diet Biosynthesis

Bile Acids

Intestine

Feces

Re-absorption

Lipoproteincatabolism

Ezetimibe

Page 13: Antihyperlipidemic Agents

Serum Cholesterol Cellular Cholesterol

Diet Biosynthesis

Bile Acids

Intestine

Feces

Re-absorption

Lipoproteincatabolism

FIBRATES

Page 14: Antihyperlipidemic Agents

Serum Cholesterol Cellular Cholesterol

Diet Biosynthesis

Bile Acids

Intestine

Feces

Re-absorption

LipoproteincatabolismBILE ACID

SEQUESTRANTS

Page 15: Antihyperlipidemic Agents

Serum Cholesterol Cellular Cholesterol

Diet Biosynthesis

Bile Acids

Intestine

Feces

Re-absorption

Lipoproteincatabolism

NicotinicAcid

Page 16: Antihyperlipidemic Agents

Serum Cholesterol Cellular Cholesterol

Diet Biosynthesis

Bile Acids

Intestine

Feces

Re-absorption

Lipoproteincatabolism

STATINS

NicotinicAcid

BILE ACIDSEQUESTRANTS

FIBRATES

Ezetimibe

Page 17: Antihyperlipidemic Agents

STATINS(ex:Atorvastatin,Cerivastatin,Fluvastatin,Lovast

atin,Pravastatin,Simvastatin,Mevastatin…etc)

Page 18: Antihyperlipidemic Agents
Page 19: Antihyperlipidemic Agents

Statins are used to treat Type II,III and V of

hyperlipidemia.

Page 20: Antihyperlipidemic Agents

How do they work?

Page 21: Antihyperlipidemic Agents

1. Inhibiting cholesterol synthesis by inhibiting HMG-CoA reductase,which plays a central role in the production of cholesterol in the liver, statins block the pathway for synthesizing cholesterol in the liver.

Page 22: Antihyperlipidemic Agents

This is significant because most circulating cholesterol comes from internal manufacture rather than the diet. When the liver can no longer produce cholesterol, levels of cholesterol in the blood will fall.

Page 23: Antihyperlipidemic Agents

2.Increasing LDL uptakeLiver cells sense the reduced levels of liver cholesterol since the intracellular synthesis of cholesterol is inhibited and cells are therefore dependent on extracellular sources of cholesterol and seek to compensate by synthesizing LDL receptors to draw cholesterol out of the circulation.

Page 24: Antihyperlipidemic Agents

LDL and VLDL are drawn out of circulation into the liver where the cholesterol is reprocessed into bile salts.

Page 25: Antihyperlipidemic Agents

Adverse effect:

• Liver: Changes in liver function occur in a small fraction of people,withdraw of the drug The liver is expected to return to normal function.

Page 26: Antihyperlipidemic Agents

• Muscle:“Myopathy" involving actual damage to muscle tissue, can be very serious, if myopathy occurs and the drugs are not stopped a condition, called “rhabdomyolysis”(is the rapid breakdown (lysis) of skeletal muscle)can be fetal.

Page 27: Antihyperlipidemic Agents

Myopathy and rhabdomyolysis are more common if people are on other cholesterol lowering drugs, particularly niacin or fibrates as well as a statin.

Page 28: Antihyperlipidemic Agents

Drug interaction:

• They increase effect of Warfarin.

• Grapefruit juice increases simvastatin levels, so should be avoided.

Page 29: Antihyperlipidemic Agents

• Patients started on some macrolide antibiotics, such as erythromycin, or azole antifungals should stop the statin for the duration of the course or should have an alternative antibiotic prescribed.

Page 30: Antihyperlipidemic Agents

FIBRATES(ex:Bezafibrate,Ciprofibrate,

Clofibrate,Gemfibrozil,Fenofibrate…etc)

Page 31: Antihyperlipidemic Agents
Page 32: Antihyperlipidemic Agents

Fibrates are used to treat Type III,IV and V of

hyperlipidemia.

Page 33: Antihyperlipidemic Agents

How do they work?

Page 34: Antihyperlipidemic Agents

Fibrates are agonists of the PPAR-α receptor in muscle, liver, and other tissues.

Page 35: Antihyperlipidemic Agents

Activation of PPAR-α signaling results in:

•Increased β-oxidation in the liver

•Decreased hepatic triglyceride secretion

Page 36: Antihyperlipidemic Agents

•Increased lipoprotein lipase activity, and thus increased VLDL clearance

•Increased HDL

•Increased clearance of remnant particles

Page 37: Antihyperlipidemic Agents

Adverse effect:

• Most fibrates can cause mild stomach upset and myopathy (muscle pain with CPK” creatine phosphokinase” elevations).

Page 38: Antihyperlipidemic Agents

• Since fibrates increase the cholesterol content of bile, they increase the risk for gallstones.

Page 39: Antihyperlipidemic Agents

Drug interaction:

• They compete with coumarin anticoagulant and some acidic drugs such as phenytoin and tolbutamide for binding with albumin and therefore increase their effect.

Page 40: Antihyperlipidemic Agents

•In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to renal failure

•They also may increase the risk of cancer

Page 41: Antihyperlipidemic Agents

Bile Acid Sequestrants

(ex: Cholestyramine,Colesevelam,Colestipol)

Page 42: Antihyperlipidemic Agents
Page 43: Antihyperlipidemic Agents

Bile acid sequestrants are used to treat Type IIa and

IIb of hyperlipidemia.

Page 44: Antihyperlipidemic Agents

How do they work?

Page 45: Antihyperlipidemic Agents

Bile acid sequestrants serve as ion exchange resins. They exchange anions such as chloride ions for bile acids. By doing so, they bind bile acids and sequester them from enterohepatic circulation.

Page 46: Antihyperlipidemic Agents

• bile acid sequestrants, along with any bile acids bound to the drug, are excreted via the feces after passage through the gastrointestinal tract

Page 47: Antihyperlipidemic Agents

• Since bile acids are biosynthesized from cholesterol, the disruption of bile acid reabsorption will decrease cholesterol levels, in particular LDL

Page 48: Antihyperlipidemic Agents

Adverse effect:

constipation, diarrhea, and flatulence. Some patients complain of the bad taste.

Page 49: Antihyperlipidemic Agents

Drug interaction:

• Interfere with intestinal absorption of some drugs such as (tetracycline,phenobarbital,digoxin,warfarin,statin,aspirin,thiazide diuretics)

Page 50: Antihyperlipidemic Agents

•They may also bind fat-soluble vitamins, such as vitamin A, vitamin D, vitamin E, and vitamin K. This effect may result in a vitamin deficiency. Hence, vitamin supplementation may be warranted.

Page 51: Antihyperlipidemic Agents

Nicotinic acid(also known as vitamin B3, niacin.Ex: : Nicolar and Niaspan…etc)

Page 52: Antihyperlipidemic Agents
Page 53: Antihyperlipidemic Agents

Nicotinic acids are used to treat Type II,III,IV and V of

hyperlipidemia.

Page 54: Antihyperlipidemic Agents

How do they work?

Page 55: Antihyperlipidemic Agents

Niacin blocks the breakdown of fats in adipose tissue. These fats are used to build VLDL in the liver, which are precursors of LDL or "bad" cholesterol.

Page 56: Antihyperlipidemic Agents

Because niacin blocks the breakdown of fats, it causes a decrease in free fatty acids in the blood and, as a consequence, decreases the secretion of VLDL and cholesterol by the liver.

Page 57: Antihyperlipidemic Agents

By lowering VLDL levels, niacin also increases the level of high-density lipoprotein (HDL) or "good" cholesterol in blood, and therefore it is sometimes prescribed for patients with low HDL, who are also at high risk of a heart attack.

Page 58: Antihyperlipidemic Agents

Adverse effect:

• dermatological conditions such as skin flushing and itching, dry skin, and skin rashes.• Gastrointestinal complaints, such as

dyspepsia (indigestion), nausea and liver toxicity.

Page 59: Antihyperlipidemic Agents

• High-dose niacin may also elevate blood sugar, thereby worsening diabetes mellitus.

• Hyperuricemia is another side effect of taking high-dose niacin, and may exacerbate gout.

Page 60: Antihyperlipidemic Agents

• Extremely high doses of niacin can also cause niacin maculopathy, a thickening of the macula and retina, which leads to blurred vision and blindness. This maculopathy is reversible after stopping niacin intake.

Page 61: Antihyperlipidemic Agents

• Side effects of hyperglycemia, cardiac arrhythmias and "birth defects in experimental animals" have also been reported.

Page 62: Antihyperlipidemic Agents

Drug interaction:

• Alcohol (Ethanol) and Hot drinksConsuming alcohol or hot drinks along with niacin might make the flushing and itching worse. And also alcohol might increase the chance of having liver damage.

Page 63: Antihyperlipidemic Agents

• Bile acid sequestrantsbile acid sequestrants can decrease how much niacin the body absorbs. This might reduce the effectiveness of niacin.Take niacin and the bile acid sequestrants at least 4-6 hours apart.

Page 64: Antihyperlipidemic Agents

•StatinsNiacin can adversely affect the muscles.statins can also affect the muscles. Taking niacin along with these medications might increase the risk of muscle problems.

Page 65: Antihyperlipidemic Agents

Ezetimibe(cholesterol absorption inhibitor,it is marketed as Zetia or Ezetrol)

Page 66: Antihyperlipidemic Agents
Page 67: Antihyperlipidemic Agents

Ezetimibe is used to treat Type II,III,IV and V of

hyperlipidemia.

Page 68: Antihyperlipidemic Agents

How do they work?

Page 69: Antihyperlipidemic Agents

Ezetimibe localises at the brush border of the small intestine, where it inhibits the absorption of cholesterol from the intestine. Specifically, it appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes.

Page 70: Antihyperlipidemic Agents

In addition to this direct effect, decreased cholesterol absorption leads to an upregulation of LDL-receptors on the surface of cells and an increased LDL-cholesterol uptake into cells, thus decreasing levels of LDL in the blood plasma which contribute to atherosclerosis and cardiovascular events.

Page 71: Antihyperlipidemic Agents

Adverse effect:

• Headache and diarrhea.

• Infrequent adverse effects include: myalgia and raised liver function test (ALT/AST) results.

Page 72: Antihyperlipidemic Agents

•Rarely hypersensitivity reactions (rash, angioedema) or myopathy may occur.

•Myalgia, rhabdomyolysis, hepatitis, pancreatitis, and thrombocytopenia were also noted.

Page 73: Antihyperlipidemic Agents

Drug interaction:

• Fenofibratefenofibrate and ezetimibe together may increase the levels of ezetimibe in the blood and also cause problems in people with gallbladder disease.

• Cyclosporinecyclosporine together with ezetimibe may increasing the risk of developing myopathy.

Page 74: Antihyperlipidemic Agents

• Warfarinlonger clotting times if the patient is currently on warfarin while on the cholesterol-lowering medication.

• Cholestyramine,Colestipol and Colesevelam These drugs bind to ezetimibe and reduce its absorption from the intestine by about 50%.

Page 75: Antihyperlipidemic Agents

References:

• Lippincott’s Illustrated Reviews• Goodman and Gilman’s Pharmacological Basis of Therapeutics• Some websites

Page 76: Antihyperlipidemic Agents

Prepared By:

• Brwa Dilshad• Hasan Mohammad• Sana Kawa• Nashmeel Dler